BeOne Medicines (ONC) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 13, 2026

Net selling: insiders sold $1.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$1.7M net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 3 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about ONC filings

Are insiders buying or selling BeOne Medicines AG (ONC) stock?

Net selling: insiders sold $1.7M and bought $0 of ONC stock on the open market in the 90 days to Nov 13, 2026, according to SEC Form 4 filings. $971K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Lee, Chan Henry (SVP, General Counsel), who sold $865K. The latest filing was on Nov 10, 2026.

Which members of Congress have traded ONC recently?

None. No member of Congress disclosed a ONC trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ONC smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on ONC

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $1.5M
3 of 3 on scheduled plans. Form 4 filings.
Congress
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about ONC filings

Are insiders buying or selling BeOne Medicines AG (ONC) stock?

Which members of Congress have traded ONC recently?

None. No member of Congress disclosed a ONC trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ONC smart-money data?

Funds

What funds are doing

3 moves · 6 mo

Buys/Adds$198.3M

Buys/Adds (3)

MI
Millennium
Israel Englander · Q2 2026 13F
$94.0M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
TS
Two Sigma
Q2 2026 13F
$71.7M
added
JC
JPMorgan Chase
Q2 2026 13F
$32.6M
added

Other smart money signals

Activist stakes, short interest & more

1 item

F1
Filing 13d GModerate
BAKER BROS. ADVISORS LP filed SC 13D/A on BeOne Medicines Ltd. (activist 7.80% stake)

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in 74.3% above what analysts expected.

Documents

Earnings releaseEX-99.1 All exhibits, including slides8-K Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Financial period

Q3 2026

Earnings per share

$3.28+74.28% beat

$1.88 expected

Revenue

$1.89B+7.49% beat

$1.76B expected

Company adjusted EPS: $4.59. Company and provider EPS differ; bases unknown.

EPS: Yahoo Finance

Next report

What the street expects next

Estimates as of Nov 11, 2026

EPS expected

$2.38

$1.85 to $3.25

Revenue expected

$1.86B

14 analysts

Last 30 days

2up1down

Analysts raising estimates

Estimate drift

+0.83

Change in 30 days

From the release

At a glance

Revenue $1.9B vs $1.8B expected, beat.
GAAP EPS $3.28; adjusted EPS $4.59.
Adjusted gross margin 90.0%.

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	$3.28est. $1.88	+74.28%beat	$1.89Best. $1.76B+7.49%	+33.8%from $1.41B
Jun 30, 2026Reported Aug 5, 2026	$2.05est. $1.63	+25.66%beat	$1.71BSEC filing	+29.6%from $1.32B
Mar 31, 2026Reported May 6, 2026	$1.96est. $0.81	+143.25%beat	$1.51BSEC filing	+35.5%from $1.12B
Dec 31, 2025Reported Feb 26, 2026	$0.58est. $1.30	-55.33%miss	CNY 1.50BAlpha Vantage	+32.8%from CNY 1.13B
Sep 30, 2025Reported Nov 6, 2025	$1.09est. $0.86	+26.74%beat	$1.41BSEC filing	+41.0%from $1.00B
Jun 30, 2025Reported Aug 6, 2025	$0.84est. $0.26	+$0.58beat	$1.32BSEC filing	+41.6%from $929.2M
Mar 31, 2025Reported May 7, 2025	$0.01est. -$0.74	+101.35%beat	$1.12BSEC filing	+48.6%from $751.7M
Dec 31, 2024Reported Feb 27, 2025	-$1.43est. -$1.01	-41.58%miss	CNY 1.13BAlpha Vantage	+77.8%from CNY 634.4M

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Prev close: $415.96
52-wk high: $424.73
52-wk low: $253.95
Mkt cap: $47.51B
P/E: 53.3x
ROE: +18.4%
Fwd P/E: 40.0x
Beta: 0.63
P/S: 7.2x
P/B: 8.2x
Profit margin: +13.9%
Op margin: +17.8%

Sep 2026 to Sep 2026

What it sold, what it cost, what was left.

RevenueProfit

Sep 2026

Income statement, 1 periods, all values in US dollars
USD	Sep 2026
What came in
RevenueTotal revenue	$1.89B
Cost of what it soldCost of revenue	$216.9M
Gross profit	$1.67B
What it spent
Research and development	$660.8M
Sales and adminSelling, general and administrative	$593.5M
Total operating expenses	$1.25B
What was left
Operating profitOperating income	$418.7M
Interest on debtInterest expense	$42.4M
Profit before tax	$410.4M
TaxIncome tax expense	$25.7M
Net profitNet income	$384.7M
EBITDAEarnings before interest, tax, depreciation, amortisation	$452.8M

Technicals

Price structure

This stock is in a strong uptrend.

Trend

Strong uptrend

100 / 100

RSI 14

67balanced

20D volatility

39%annualized

52-week range

$415.96

$253.95$424.73

20D support

$347.61recent floor

20D resistance

$424.73recent ceiling

Returns

5D +7.4%20D +11.2%60D +10.4%

Price vs moving averages

SMA20 +8.2%SMA50 +13.0%SMA200 +27.0%

Volume pace

1.20xvs prior 20D

News

What the news says

8 articles · 7 days

Coverage leans bullish

2 bullish · 5 neutral · 1 bearish

BeiGene Q3 Profit Surges 208% as CLSA Raises Hong Kong Target Price to HK$336.8
NeutralNov 10
BeiGene's First Three Quarters Profit Surges More Than Fourfold, EPS 4.16 Yuan
BullishNov 9
Weekly Recap: 2026 outlook raised and BRUKINSA sales rise 33.7%
BullishNov 9
BeiGene Ltd (49BA.MU) Seasonal returns chart
NeutralNov 6
BeiGene Ltd (49BA.DU) Seasonal returns chart - Yahoo Finance
NeutralNov 4
BeiGene Ltd (49BA.DU) Seasonal returns chart
Leans bearishNov 3
BeiGene Ltd (49BA.MU) Seasonal returns chart
NeutralNov 1
BeiGene Ltd (49BA.MU) Seasonal Returns Chart - Yahoo Finance
NeutralNov 1

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 5, 2026

$3.28est. $1.88

+74.28%

$1.89Best. $1.76B+7.49%

+33.8%from $1.41B

Jun 30, 2026Aug 5, 2026

$2.05est. $1.63

+25.66%

$1.71BSEC filing

+29.6%from $1.32B

Mar 31, 2026May 6, 2026

$1.96est. $0.81

+143.25%

$1.51BSEC filing

+35.5%from $1.12B

Dec 31, 2025Feb 26, 2026

$0.58est. $1.30

-55.33%

CNY 1.50BAlpha Vantage

+32.8%from CNY 1.13B

Sep 30, 2025Nov 6, 2025

$1.09est. $0.86

+26.74%

$1.41BSEC filing

+41.0%from $1.00B

Jun 30, 2025Aug 6, 2025

$0.84est. $0.26

+$0.58

$1.32BSEC filing

+41.6%from $929.2M

Mar 31, 2025May 7, 2025

$0.01est. -$0.74

+101.35%

$1.12BSEC filing

+48.6%from $751.7M

Dec 31, 2024Feb 27, 2025

-$1.43est. -$1.01

-41.58%

CNY 1.13BAlpha Vantage

+77.8%from CNY 634.4M

Income statement, 1 periods, all values in US dollars
USD	Sep 2026
What came in
RevenueTotal revenue	$1.89B
Cost of what it soldCost of revenue	$216.9M
Gross profit	$1.67B
What it spent
Research and development	$660.8M
Sales and adminSelling, general and administrative	$593.5M
Total operating expenses	$1.25B
What was left
Operating profitOperating income	$418.7M
Interest on debtInterest expense	$42.4M
Profit before tax	$410.4M
TaxIncome tax expense	$25.7M
Net profitNet income	$384.7M
EBITDAEarnings before interest, tax, depreciation, amortisation	$452.8M

USD

Sep 2026

What came in

RevenueTotal revenue

$1.89B

Cost of what it soldCost of revenue

$216.9M

Gross profit

$1.67B

What it spent

Research and development

$660.8M

Sales and adminSelling, general and administrative

$593.5M

Total operating expenses

$1.25B

What was left

Operating profitOperating income

$418.7M

Interest on debtInterest expense

$42.4M

Profit before tax

$410.4M

TaxIncome tax expense

$25.7M

Net profitNet income

$384.7M

EBITDAEarnings before interest, tax, depreciation, amortisation

$452.8M

BeOne Medicines AG

Smart money at a glance

What do analysts expect?

Questions about ONC filings

Smart money on ONC

Questions about ONC filings

What funds are doing

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 74.3% above what analysts expected.

What the street expects next

At a glance

Previous reports

What it sold, what it cost, what was left.

Price structure

What the news says

Ask it in Claude or ChatGPT.

BeOne Medicines AG

Smart money at a glance

What do analysts expect?

Questions about ONC filings

Smart money on ONC

Questions about ONC filings

What funds are doing

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 74.3% above what analysts expected.

What the street expects next

At a glance

Previous reports

What it sold, what it cost, what was left.

Price structure

What the news says

Ask it in Claude or ChatGPT.

BeOne Medicines AG

Overview

Questions about ONC filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Ask it in Claude or ChatGPT.

BeOne Medicines AG

Overview

Questions about ONC filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Ask it in Claude or ChatGPT.